Perseus Proteomics Inc. [4882.T]
TOKYO, Mar 31 (Pulse News Wire) – Perseus Proteomics Inc. (4882.T) disclosed its fiscal year 2026 revenue forecast amid ongoing uncertainties surrounding its pipeline activities.
The company now expects sales of ¥135 million, operating profit of ¥--¥772 million, ordinary profit of ¥--¥707 million, and net income of ¥--¥758 million per share for the fiscal year ending March 31, 2026. Previously, the company had refrained from providing forecasts due to numerous unpredictable factors associated with the development and potential licensing of its PPMX-T002 and PPMX-T003 projects. Despite continued efforts, no definitive agreements have been reached yet, leading to significant variability in projected revenues and expenses.
Looking ahead, Perseus Proteomics plans to continue its licensing initiatives for all pipelines while managing costs. Research and development expenditures are anticipated to amount to ¥604 million, administrative expenses to ¥287 million, and selling and general administration fees to ¥892 million. It should be noted that actual results could differ from these projections due to various unforeseen circumstances.
🟢 Confidence: High AI-translated content.